drugset / Trial / NCT06967610
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To learn if the drug combination pirtobrutinib, venetoclax, and obinutuzumab can help to control relapsed CLL/SLL.
Timeline
- Start
- 2025-07-15
- Primary completion
- 2031-06-01
- Completion
- 2033-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Obinutuzumab | Monoclonal antibody | 100 mg | Intravenous |
| Subject | Pirtobrutinib | Other / unclassified | 200 mg | Oral |
| Subject | Venetoclax | Small molecule | — | Oral |